Long term outcomes of breast primary sarcomas and malignant phyllodes tumors: 20 years observational analysis of the BEAM∗ study group. (∗the breast European association for mesenchymal tumors)
European Journal of Surgical Oncology · 2025
DOI: 10.1016/j.ejso.2025.110265 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Alejandro M Sanchez und 48 weiteren Autor:innen. Beteiligte Einrichtung: Multidisciplinary Breast Center - Department of Women's, Children's and Public Health Sciences, "A. Gemelli" University Hospital Foundation IRCCS. 00…. Hauptthemen laut MEDLINE: Phyllodes Tumor, Breast Neoplasms, Sarcoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Primary breast sarcomas (PBS) and malignant phyllodes tumors (MPT) represent less than 1 % of breast malignancies. Current evidence relies on heterogeneous retrospective series, resulting in controversial therapeutic approaches. This study aimed to analyze long-term outcomes in a large multicentric cohort treated with consistent strategies. MATERIALS AND METHODS: We conducted a multicentric retrospective study involving 113 patients treated for PBS (n = 42), MPT (n = 47), and mixed cases (MC, n = 24) at 11 European breast units between 2000 and 2020. Primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS), local recurrence rate (LRR), and positive margin, re-excision, and axillary involvement rates. Survival analyses were performed using the Kaplan-Meier method and log-rank test. RESULTS: With a median follow-up of 95 months, the 10-year OS, DFS, and LRR for the entire cohort were 75.2 %, 61.9 %, and 18.4 %, respectively. Mixed cases exhibited the poorest outcomes (10-year OS: 57.6 %, DFS: 46.1 %), followed by PBS (OS: 67.5 %, DFS: 46.5 %). MPT demonstrated better survival rates (OS: 89.2 %, DFS: 82.9 %). Significant survival factors included histological subtype, surgical margins, and age. Notably, adjuvant chemotherapy was linked to worse outcomes (HR 5.11, 95 % CI 2.16-12.09, p < 0.001 for OS), likely indicating selection bias for high-risk patients. CONCLUSIONS: This study represents the largest European series with a homogeneous treatment approach and long-term follow-up. MC emerge as a distinct high-risk entity, with outcomes akin to angiosarcomas. While surgery remains the cornerstone of treatment, our data challenge the current paradigm regarding adjuvant chemotherapy, highlighting the need for new strategies, particularly for high-risk subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Multidisciplinary Breast Center - Department of Women's, Children's and Public Health Sciences, "A. Gemelli" University Hospital Foundation IRCCS. 00168 Rome, Italy.
- Facility of Epidemiology & Biostatistics - G-STEP, "A. Gemelli" University Hospital Foundation IRCCS. 00168 Rome, Italy.
- Division of Medical Oncology, "A. Gemelli" University Hospital Foundation IRCCS. 00168 Rome, Italy.
- Precision Medicine in Senology Unit, "A. Gemelli" University Hospital Foundation IRCCS. 00168 Rome, Italy.
- Gynecologic and Breast Pathology Unit, Department of Women's, Children's and Public Health Sciences, "A. Gemelli" University Hospital Foundation IRCCS. 00168 Rome, Italy. Electronic address: angela.santoro@policlinicoge…
- Gynecologic and Breast Pathology Unit, Department of Women's, Children's and Public Health Sciences, "A. Gemelli" University Hospital Foundation IRCCS. 00168 Rome, Italy.
Zitieren
APA
Sanchez, A. M., De Lauretis, F., Bucaro, A., Pirrottina, C. V., Borghesan, N., Franco, A., Scardina, L., Giannarelli, D., Di Leone, A., Masetti, R., Orlandi, A., Fabi, A., Palazzo, A., Poli, I., Santoro, A., Mulè, A., D'Alessandris, N., Marazzi, F., Masiello, V., …, & BEAM Study Group (2025). Long term outcomes of breast primary sarcomas and malignant phyllodes tumors: 20 years observational analysis of the BEAM∗ study group. (∗the breast European association for mesenchymal tumors). European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.110265
Vancouver
Sanchez AM, De Lauretis F, Bucaro A, Pirrottina CV, Borghesan N, Franco A, et al. Long term outcomes of breast primary sarcomas and malignant phyllodes tumors: 20 years observational analysis of the BEAM∗ study group. (∗the breast European association for mesenchymal tumors). European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.110265
BibTeX
@article{Sanchez2025,
author = {Sanchez, Alejandro M and De Lauretis, Flavia and Bucaro, Angela and Pirrottina, Chiara V and Borghesan, Niccolò and Franco, Antonio and Scardina, Lorenzo and Giannarelli, Diana and Di Leone, Alba and Masetti, Riccardo and Orlandi, Armando and Fabi, Alessandra and Palazzo, Antonella and Poli, Ilaria and Santoro, Angela and Mulè, Antonino and D'Alessandris, Nicoletta and Marazzi, Fabio and Masiello, Valeria and Verusio, Valeria and Veronesi, Paolo and Pennacchioli, Elisabetta and Mattar, Denise and Lobrano, Renato and Brancaccio, Roberta and Ferraresi, Virginia and Onesti, Elisa Concetta and Vari, Sabrina and Gentile, Damiano and Tinterri, Corrado and Masannat, Yazan and Lendore, Jessica and Rasheed, Ammara and Aristei, Cynthia and Epifani, Valeria and Foschini, Maria Pia and Maestri, Antonio and D'Angelo, Elisa and Cucchi, Maria Cristina and Baldissera, Antonella and Vincenzi, Bruno and Vitale, Valeria and Lombardi, Augusto and Cejas Arjona, Francisco Javier and Torres, Pilar Rioja and Clough, Krishna and Millochau, Jenny C and Franceschini, Gianluca and BEAM Study Group, BEAM Study Group},
title = {Long term outcomes of breast primary sarcomas and malignant phyllodes tumors: 20 years observational analysis of the BEAM∗ study group. (∗the breast European association for mesenchymal tumors)},
journal = {European Journal of Surgical Oncology},
year = {2025},
doi = {10.1016/j.ejso.2025.110265}
}
EUVIMED